Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL452873 | 0.77 | GAA (0.44) | GAAMAPT | |
| SCHEMBL29774450 | 0.77 | GAA (0.44) | GAAMAPT | |
| SCHEMBL19679 | 0.75 | — | — | |
| SCHEMBL31079568 | 0.63 | GAA (0.39) | GAAMAPT | |
| SCHEMBL15860817 | 0.62 | GAA (0.37) | GAAMAPT | |
| SCHEMBL160159 | 0.62 | GAA (0.38) | GAAMAPT | |
| SCHEMBL31030868 | 0.62 | ALOX15 (0.34) | GAAMAPT | |
| SCHEMBL290837 | 0.62 | — | — | |
| SCHEMBL29650387 | 0.60 | — | — | |
| SCHEMBL56377 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150105386-A1 | 4-(4-PYRIDINYL)-BENZAMIDES AND THEIR USE AS ROCK ACTIVITY MODULATORS | ABBVIE DEUTSCHLAND (DE) | 2015-04-16 | — | — | US | disclosed |
| US-8895749-B2 | 4-(4-pyridinyl)-benzamides and their use as rock activity modulators | ABBVIE INC. (US) | 2014-11-25 | — | — | US | disclosed |
| US-20130310378-A1 | 4-(4-PYRIDINYL)-BENZAMIDES AND THEIR USE AS ROCK ACTIVITY MODULATORS | ABBVIE INC. (US) | 2013-11-21 | — | — | US | disclosed |
| US-8445686-B2 | 4-(4-pyridinyl)-benzamides and their use as rock activity modulators | ABBVIE INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-20100273828-A1 | 4-(4-PYRIDINYL)-BENZAMIDES AND THEIR USE AS ROCK ACTIVITY MODULATORS | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310378-A1 | 4-(4-PYRIDINYL)-BENZAMIDES AND THEIR USE AS ROCK ACTIVITY MODULATORS | GABRR3, ROCK1, ROCK2 | GAA 4436/4885MAPT 4581/4885 |
| US-20150105386-A1 | 4-(4-PYRIDINYL)-BENZAMIDES AND THEIR USE AS ROCK ACTIVITY MODULATORS | GABRR3, ROCK1, ROCK2 | GAA 4438/4885MAPT 4579/4885 |
| US-20100273828-A1 | 4-(4-PYRIDINYL)-BENZAMIDES AND THEIR USE AS ROCK ACTIVITY MODULATORS | GABRR3, ROCK1, ROCK2 | GAA 4436/4885MAPT 4581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.